MacroGenics MGNX 深 滬
已收盤 09-18 16:00:00 美东时间
3.30
-0.065
-1.93%
華盛通- 最 高3.401
- 今 開3.37
- 成交量 61.32万股
- 最 低 3.25
- 昨 收 3.365
- 總市值 2.05亿
- 52周最高 21.88
- 市盈率 靜 --
- 換手率 0.99%
- 52周最低 3.14
- 委 比 66.19%
- 總股本 6202.94万
- 歷史最高 41.00
- 量 比 1.04
- 振 幅 4.49%
- 歷史最低 2.13
- 每 手 1
- 風險率 5.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多快讯 | MacroGenics股价下跌7.4%，数据显示该公司的前列腺癌药物安全性状况恶化。
MacroGenics Shares Down 7.4% as Data Shows Worsening Safety Profile for Co's Pr...
09-17 01:20
Evercore ISI Sticks to Their Buy Rating for MacroGenics (MGNX)
In a report released today, Jonathan Miller from Evercore ISI maintained a Buy ...
09-16 20:25
MacroGenics (MGNX) Receives a Hold from TD Cowen
In a report released today, Tara Bancroft from TD Cowen maintained a Hold ratin...
09-16 19:46
创新药的新战场
虽然行业仍处于寒冬时期，但事实上从去年以来，中国biotech在创新的靶点和机理上不断有新的故事在发生。 2024年，中国在药物靶点研究领域新增295个新靶点...
09-12 08:06
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 2, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between Mar...
09-03 05:30
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Medtronic (MDT)
Companies in the Healthcare sector have received a lot of coverage today as ana...
08-21 18:20
Evaluating Macrogenics: Insights From 8 Financial Analysts
Across the recent three months, 8 analysts have shared their insights on Macrog...
08-15 23:01
Citigroup Maintains Buy on Macrogenics, Lowers Price Target to $14
Citigroup analyst Yigal Nochomovitz maintains Macrogenics (NASDAQ:MGNX) with a Buy and lowers the price target from $16 to $14.
08-15 22:25
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MacroGenics To Contact Him Directly To Discuss Their Opti...
08-14 21:50
Macrogenics Q2 EPS $(0.89) Misses $(0.59) Estimate, Sales $10.80M Miss $21.24M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.59) by 50.85 percent. This is a 196.74 percent decrease over earnings of $0.92 per share from
08-07 04:38
